<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03352557</url>
  </required_header>
  <id_info>
    <org_study_id>251AD201</org_study_id>
    <secondary_id>2017-002901-37</secondary_id>
    <nct_id>NCT03352557</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease</brief_title>
  <acronym>TANGO</acronym>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the placebo-controlled period is to evaluate the safety and&#xD;
      tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to&#xD;
      Alzheimer's disease (AD) or with mild AD. The secondary objectives of the placebo-controlled&#xD;
      period are to evaluate the efficacy of multiple doses of BIIB092 in slowing cognitive and&#xD;
      functional impairment in participants with MCI due to AD or with mild AD, and to evaluate the&#xD;
      immunogenicity of BIIB092 after multiple doses in participants with MCI due to AD or with&#xD;
      mild AD.&#xD;
&#xD;
      The primary objective of the long-term extension period is to evaluate the long-term safety&#xD;
      and tolerability of BIIB092 in participants with MCI due to AD or with mild AD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study (NCT03352557) was terminated based on lack of efficacy following the&#xD;
    placebo-controlled period readout.&#xD;
  </why_stopped>
  <start_date type="Actual">May 3, 2018</start_date>
  <completion_date type="Actual">August 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PC Period: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 to Week 78 (participants who entered LTE period); Day 1 up to Week 90 (participants who did not LTE period)</time_frame>
    <description>AE is any untoward medical occurrence in participant or clinical investigation participant administered pharmaceutical product and that does not necessarily have causal relationship with this treatment. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of medicinal (investigational) product, whether or not related to medicinal (investigational) product. SAE is any untoward medical occurrence that at any dose, results in death; in view of investigator places participant at immediate risk of death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in congenital anomaly/birth defect; is medically important event. Participants who completed treatment period in PC period and did not enter LTE period were to be assessed at Week 90 (14 weeks after end of treatment) as safety follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LTE Period: Percentage of Participants With AEs and SAEs</measure>
    <time_frame>From Week 80 to Week 173</time_frame>
    <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose, results in death; in the view of the investigator places the participant at immediate risk of death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; is a medically important event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PC Period: Change From Baseline Over Time at Week 78 on the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score</measure>
    <time_frame>Baseline, Week 78</time_frame>
    <description>The CDR-SB is a validated clinical assessment of global function in participants with AD. The CDR is comprised of 6 domains: Memory, Orientation, Judgment and Problem Solving, Community Affairs, Home and Hobbies, and Personal Care. CDR-SB is the sum of the scores for these 6 domains. Impairment is scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or &quot;box scores&quot;, can be added together to give the CDR-SB score which ranges from 0 (none) to 18 (severe impairment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PC Period: Percentage of Participants With Anti-BIIB092 Antibodies in Serum</measure>
    <time_frame>Baseline up to Week 76</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">654</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Low-dose BIIB092</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) infusion once every 4 weeks OR once every 12 weeks and placebo at the other 4-week dosing visits to maintain the treatment blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium-dose BIIB092</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) infusion once every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose BIIB092</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) infusion once every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous (IV) infusion once every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB092</intervention_name>
    <description>Administered as specified in treatment arm.</description>
    <arm_group_label>High-dose BIIB092</arm_group_label>
    <arm_group_label>Low-dose BIIB092</arm_group_label>
    <arm_group_label>Medium-dose BIIB092</arm_group_label>
    <other_name>Formally known as BMS 986168</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as specified in treatment arm.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Must have a gradual and progressive change in memory function over more than 6 months.&#xD;
&#xD;
          -  Must meet all of the clinical criteria for mild cognitive impairment (MCI) due to&#xD;
             Alzheimer's disease (AD) or mild AD and must have&#xD;
&#xD;
          -  Objective evidence of cognitive impairment at Screening&#xD;
&#xD;
          -  Clinical Dementia Rating Scale (CDR) global score of 0.5 for MCI due to AD or 0.5 or 1&#xD;
             for mild AD&#xD;
&#xD;
          -  Mini-Mental State Examination (MMSE) score of 22 to 30 (inclusive)&#xD;
&#xD;
          -  CDR Memory Box score of â‰¥0.5&#xD;
&#xD;
          -  Must consent to apolipoprotein E (ApoE) genotyping&#xD;
&#xD;
          -  Must have 1 informant/study partner&#xD;
&#xD;
          -  Must have amyloid beta positivity confirmed at Screening&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Any medical or neurological/neurodegenerative condition (other than AD) that, in the&#xD;
             opinion of the Investigator, might be a contributing cause to the participant's&#xD;
             cognitive impairment or could lead to discontinuation, lack of compliance,&#xD;
             interference with study assessments, or safety concerns&#xD;
&#xD;
          -  Clinically significant, unstable psychiatric illness&#xD;
&#xD;
          -  Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of&#xD;
             consciousness in the past 1 year&#xD;
&#xD;
          -  Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities&#xD;
&#xD;
          -  History of unstable angina, myocardial infarction, chronic heart failure or clinically&#xD;
             significant conduction abnormalities within 1 year prior to Screening Visit 1&#xD;
&#xD;
          -  Indication of impaired renal or liver function&#xD;
&#xD;
          -  Alcohol or substance abuse in past 1 year&#xD;
&#xD;
          -  Clinically significant systemic illness or serious infection within 30 days prior to&#xD;
             or during the screening period&#xD;
&#xD;
          -  Use of allowed medications for chronic conditions at doses that have not been stable&#xD;
             for at least 4 weeks prior to Screening Visit 1 and during the screening period up to&#xD;
             Study Day 1, or use of AD medications at doses that have not been stable for at least&#xD;
             8 weeks prior to Screening Visit 1 and during the screening period up to Study Day 1.&#xD;
&#xD;
          -  Use of any medications that, in the opinion of the Investigator, may contribute to&#xD;
             cognitive impairment, put the participants at higher risk for adverse events (AEs), or&#xD;
             impair the participant's ability to perform cognitive testing or complete study&#xD;
             procedures.&#xD;
&#xD;
          -  Contraindications to study procedures&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xenoscience Inc</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dignity Health</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Center, Inc.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Center of Southern California</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Positron Research International</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropain Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V Royter, MD, APMC</name>
      <address>
        <city>Hanford</city>
        <state>California</state>
        <zip>93230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irvine Center for Clinical Research, Inc.</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center for Clinical Studies West</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary S. Easton Center for Alzheimer's Disease Research, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network, Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Syrentis Clinical Research</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Invicro</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School Of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JEM Research Institute</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research Center of Southwest Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34997</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axiom Clinical Research of Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - The Villages</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Cognitive Neurology Clinic &amp; ADRC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital Department of Neurology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115 5804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <zip>01844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Center for Memory</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donald S. Marks, M.D., P.C.</name>
      <address>
        <city>Plymouth</city>
        <state>Massachusetts</state>
        <zip>02360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Center for Brain Health</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Medical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cognitive Research Center of New Jersey</name>
      <address>
        <city>Springfield</city>
        <state>New Jersey</state>
        <zip>07081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Memory Enhancement Center of NJ</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center PRIME</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AD-CARE, University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Mood &amp; Memory Research Institute</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Clinic, PC</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Memory Clinic, Inc.</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognition Health</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caulfield Hospital</name>
      <address>
        <city>Caulfield</city>
        <state>Victoria</state>
        <zip>3162</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg West</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg - HÃ´pital Hautepierre</name>
      <address>
        <city>Strasbourg Cedex</city>
        <state>Bas Rhin</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pellegrin - HÃ´pital Pellegrin</name>
      <address>
        <city>Bordeaux Cedex</city>
        <state>Gironde</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital La Grave</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <state>Haute Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Pontchaillou</name>
      <address>
        <city>Rennes cedex 2</city>
        <state>Ille Et Vilaine</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - Hopital Nord LaÃ«nnec</name>
      <address>
        <city>Nantes cedex 1</city>
        <state>Loire Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital LariboisiÃ¨re</name>
      <address>
        <city>Paris cedex 10</city>
        <state>Paris</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital des Chapennes</name>
      <address>
        <city>Villeurbanne</city>
        <state>Rhone</state>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum fur Neurologie und Psychiatrie</name>
      <address>
        <city>BÃ¶blingen</city>
        <state>Baden Wuertemberg</state>
        <zip>71034</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISPG - Institut fuer Studien zur Psychischen Gesundheit</name>
      <address>
        <city>Mannheim</city>
        <state>Baden Wuerttemberg</state>
        <zip>68165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut fuer Schlaganfall- und Demenzforschung (ISD)</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn AoeR</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Altenburger Land GmbH</name>
      <address>
        <city>Altenburg</city>
        <state>Thueringen</state>
        <zip>04600</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Berlin Buch, Experimental and Clinical Research Center (ECRC)</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Centro San Giovanni di Dio Fatebenefratelli</name>
      <address>
        <city>Brescia</city>
        <zip>25125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Policlinico Paolo</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Umberto I - UniversitÃ  di Roma La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULSS 6 Vicenza</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Obu-shi</city>
        <state>Aichi-Ken</state>
        <zip>474-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba-Ken</state>
        <zip>263-0043</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa-Ken</state>
        <zip>213-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto-Fu</state>
        <zip>600-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kurashiki-shi</city>
        <state>Okayama-Ken</state>
        <zip>710-0813</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka-Fu</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PALLMED Sp. z o.o.</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-023</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Senior</name>
      <address>
        <city>Sopot</city>
        <zip>81-855</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne NeuroProtect</name>
      <address>
        <city>Warszawa</city>
        <zip>01-697</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazowiecki Szpital WojewÃ³dzki w Warszawie Sp z oo</name>
      <address>
        <city>Warszawa</city>
        <zip>03-242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAE Oroitu</name>
      <address>
        <city>Getxo</city>
        <state>Vizcaya</state>
        <zip>48993</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacio ACE</name>
      <address>
        <city>Barcelona</city>
        <zip>8028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Ruber Juan Bravo</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Victoria Eugenia</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SkÃ¥nes Universitetssjukhus</name>
      <address>
        <city>Malmo</city>
        <zip>212 24</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset, MÃ¶lndal Sjukhus</name>
      <address>
        <city>Molndal</city>
        <zip>43180</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset, Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <results_first_submitted>August 26, 2022</results_first_submitted>
  <results_first_submitted_qc>October 18, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2022</results_first_posted>
  <last_update_submitted>October 18, 2022</last_update_submitted>
  <last_update_submitted_qc>October 18, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild cognitive impairment</keyword>
  <keyword>Alzheimer's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/</ipd_description>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT03352557/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Placebo-Controlled Period</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 31, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT03352557/SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Long-Term Extension Period</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 16, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT03352557/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at approximately 100 investigational sites from 03 May 2018 to 30 August 2021.</recruitment_details>
      <pre_assignment_details>A total of 654 participants with Alzheimer's Disease (AD) were enrolled and randomized to receive placebo or BIIB092 125/375/600/2000 milligrams(mg) in Placebo-Controlled (PC) period. Following PC period, 521 participants entered and 516 were dosed in Long-term Extension (LTE) period, and no participants completed the study due to early termination of the study. WBP/G=Withdrawal by Parent/Guardian</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PC Period: Placebo</title>
          <description>Participants received BIIB092-matching placebo, intravenous (IV) infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
        </group>
        <group group_id="P2">
          <title>PC Period: BIIB092 125 mg/4 Week</title>
          <description>Participants received BIIB092, 125 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
        </group>
        <group group_id="P3">
          <title>PC Period: BIIB092 375 mg/12 Week</title>
          <description>Participants received BIIB092, 375 mg, IV infusion, on Day 1 and then once every 12 weeks for 76 weeks during the PC period.</description>
        </group>
        <group group_id="P4">
          <title>PC Period: BIIB092 600 mg/4 Week</title>
          <description>Participants received BIIB092, 600 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
        </group>
        <group group_id="P5">
          <title>PC Period: BIIB092 2000 mg/4 Week</title>
          <description>Participants received BIIB092, 2000 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
        </group>
        <group group_id="P6">
          <title>LTE Period: BIIB092 125 mg/4 Week</title>
          <description>Participants who received BIIB092, 125 mg, IV infusion during the PC period, continued to receive BIIB092, 125 mg, IV infusion once every 4 weeks from Week 80 to Week 155 during the LTE period.</description>
        </group>
        <group group_id="P7">
          <title>LTE Period: BIIB092 375 mg/12 Week</title>
          <description>Participants who received BIIB092, 375 mg, IV infusion during the PC period, continued to receive BIIB092, 375 mg, IV infusion once every 12 weeks from Week 80 to Week 155 during the LTE period.</description>
        </group>
        <group group_id="P8">
          <title>LTE Period: BIIB092 600 mg/4 Week</title>
          <description>Participants who received BIIB092, 600 mg, IV infusion during the PC period, continued to receive BIIB092, 600 mg, IV infusion once every 4 weeks from Week 80 to Week 155 during the LTE period.</description>
        </group>
        <group group_id="P9">
          <title>LTE Period: BIIB092 2000 mg/4 Week - Early Start</title>
          <description>Participants who received BIIB092, 2000 mg, IV infusion during the PC period, continued to receive BIIB092, 2000 mg, IV infusion once every 4 weeks from Week 80 to Week 155 during the LTE period.</description>
        </group>
        <group group_id="P10">
          <title>LTE Period: BIIB092 2000 mg/4 Week - Late Start</title>
          <description>Participants who received BIIB092-matching placebo, IV infusion during the PC period, received BIIB092, 2000 mg, IV infusion once every 4 weeks from Week 80 to Week 155 during the LTE period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>PC Period: Day 1 to Week 78</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="106"/>
                <participants group_id="P5" count="218"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="106"/>
                <participants group_id="P5" count="214"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="106"/>
                <participants group_id="P5" count="214"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Antidrug Antibody (ADA) Evaluable Set</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="105"/>
                <participants group_id="P5" count="212"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="91"/>
                <participants group_id="P5" count="175"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized by Mistake</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Participant-Study Visit Burden/Scheduling Conflicts</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Participant-Concern About Study Procedures/Perceived Risks</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Participant-Relocation (Moving or Has Moved)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Participant-Desire for Change in Treatment (Unrelated to Safety)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Participant-Other</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>WBP/G-Study Visit Burden/Scheduling Conflicts</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>WBP/G-Concern About Study Procedures/Perceived Risks</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>WBP/G-Desire for Change in Treatment (Unrelated to Safety)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>WBP/G-Unable to Continue to Enable Participation due to Illness/Hospitalization/Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>WBP/G-Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision-Unrelated to Safety</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Dosed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>LTE Period: Week 80 to Week 173</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="46">2 PC completers did not enter LTE.</participants>
                <participants group_id="P7" count="49">1 PC completer did not enter LTE.</participants>
                <participants group_id="P8" count="90">1 PC completer did not enter LTE.</participants>
                <participants group_id="P9" count="169">6 PC completers did not enter LTE.</participants>
                <participants group_id="P10" count="167">5 PC completers did not enter LTE.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="45"/>
                <participants group_id="P7" count="49"/>
                <participants group_id="P8" count="89"/>
                <participants group_id="P9" count="168"/>
                <participants group_id="P10" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="46"/>
                <participants group_id="P7" count="49"/>
                <participants group_id="P8" count="90"/>
                <participants group_id="P9" count="169"/>
                <participants group_id="P10" count="167"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="38"/>
                <participants group_id="P7" count="49"/>
                <participants group_id="P8" count="75"/>
                <participants group_id="P9" count="151"/>
                <participants group_id="P10" count="154"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Participant-Study Visit Burden/Scheduling Conflicts</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Participant-Relocation (Moving or Has Moved)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Participant-Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>WBP/G-Study Visit Burden/Scheduling Conflicts</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>WBP/G-Concern About Study Procedures/Perceived Risks</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>WBP/G-Relocation (Moving or Has Moved)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>WBP/G-Unable to Continue to Enable Participation due to Illness/Hospitalization/Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>WBP/G-Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized participants included enrolled participants who received a randomization treatment assignment from the Interactive Response Technology (BIIB092 or placebo).</population>
      <group_list>
        <group group_id="B1">
          <title>PC Period: Placebo</title>
          <description>Participants received BIIB092-matching placebo, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
        </group>
        <group group_id="B2">
          <title>PC Period: BIIB092 125 mg/4 Week</title>
          <description>Participants received BIIB092, 125 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
        </group>
        <group group_id="B3">
          <title>PC Period: BIIB092 375 mg/12 Week</title>
          <description>Participants received BIIB092, 375 mg, IV infusion, on Day 1 and then once every 12 weeks for 76 weeks during the PC period.</description>
        </group>
        <group group_id="B4">
          <title>PC Period: BIIB092 600 mg/4 Week</title>
          <description>Participants received BIIB092, 600 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
        </group>
        <group group_id="B5">
          <title>PC Period: BIIB092 2000 mg/4 Week</title>
          <description>Participants received BIIB092, 2000 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="214"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="58"/>
            <count group_id="B4" value="106"/>
            <count group_id="B5" value="218"/>
            <count group_id="B6" value="654"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.8" spread="6.63"/>
                    <measurement group_id="B2" value="70.4" spread="6.80"/>
                    <measurement group_id="B3" value="70.3" spread="6.79"/>
                    <measurement group_id="B4" value="69.7" spread="6.66"/>
                    <measurement group_id="B5" value="69.4" spread="7.11"/>
                    <measurement group_id="B6" value="69.7" spread="6.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="114"/>
                    <measurement group_id="B6" value="329"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="104"/>
                    <measurement group_id="B6" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="103"/>
                    <measurement group_id="B5" value="208"/>
                    <measurement group_id="B6" value="627"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="98"/>
                    <measurement group_id="B5" value="206"/>
                    <measurement group_id="B6" value="611"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PC Period: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>AE is any untoward medical occurrence in participant or clinical investigation participant administered pharmaceutical product and that does not necessarily have causal relationship with this treatment. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of medicinal (investigational) product, whether or not related to medicinal (investigational) product. SAE is any untoward medical occurrence that at any dose, results in death; in view of investigator places participant at immediate risk of death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in congenital anomaly/birth defect; is medically important event. Participants who completed treatment period in PC period and did not enter LTE period were to be assessed at Week 90 (14 weeks after end of treatment) as safety follow-up.</description>
        <time_frame>Day 1 to Week 78 (participants who entered LTE period); Day 1 up to Week 90 (participants who did not LTE period)</time_frame>
        <population>The safety analysis set included all randomized participants who received at least one dose of study treatment (BIIB092 or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>PC Period: Placebo</title>
            <description>Participants received BIIB092-matching placebo, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
          </group>
          <group group_id="O2">
            <title>PC Period: BIIB092 125 mg/4 Week</title>
            <description>Participants received BIIB092, 125 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
          </group>
          <group group_id="O3">
            <title>PC Period: BIIB092 375 mg/12 Week</title>
            <description>Participants received BIIB092, 375 mg, IV infusion, on Day 1 and then once every 12 weeks for 76 weeks during the PC period.</description>
          </group>
          <group group_id="O4">
            <title>PC Period: BIIB092 600 mg/4 Week</title>
            <description>Participants received BIIB092, 600 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
          </group>
          <group group_id="O5">
            <title>PC Period: BIIB092 2000 mg/4 Week</title>
            <description>Participants received BIIB092, 2000 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
          </group>
        </group_list>
        <measure>
          <title>PC Period: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>AE is any untoward medical occurrence in participant or clinical investigation participant administered pharmaceutical product and that does not necessarily have causal relationship with this treatment. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of medicinal (investigational) product, whether or not related to medicinal (investigational) product. SAE is any untoward medical occurrence that at any dose, results in death; in view of investigator places participant at immediate risk of death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in congenital anomaly/birth defect; is medically important event. Participants who completed treatment period in PC period and did not enter LTE period were to be assessed at Week 90 (14 weeks after end of treatment) as safety follow-up.</description>
          <population>The safety analysis set included all randomized participants who received at least one dose of study treatment (BIIB092 or placebo).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6"/>
                    <measurement group_id="O2" value="86.2"/>
                    <measurement group_id="O3" value="82.8"/>
                    <measurement group_id="O4" value="88.7"/>
                    <measurement group_id="O5" value="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1"/>
                    <measurement group_id="O2" value="10.3"/>
                    <measurement group_id="O3" value="10.3"/>
                    <measurement group_id="O4" value="12.3"/>
                    <measurement group_id="O5" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>LTE Period: Percentage of Participants With AEs and SAEs</title>
        <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose, results in death; in the view of the investigator places the participant at immediate risk of death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; is a medically important event.</description>
        <time_frame>From Week 80 to Week 173</time_frame>
        <population>The safety analysis set included all randomized participants who received at least one dose of study treatment (BIIB092 or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>LTE Period: BIIB092 125 mg/4 Week</title>
            <description>Participants who received BIIB092, 125 mg, IV infusion during the PC Period, continued to receive BIIB092, 125 mg, IV infusion once every 4 weeks from Week 80 to Week 155 during the LTE period.</description>
          </group>
          <group group_id="O2">
            <title>LTE Period: BIIB092 375 mg/12 Week</title>
            <description>Participants who received BIIB092, 375 mg, IV infusion during the PC Period, continued to receive BIIB092, 375 mg, IV infusion once every 12 weeks from Week 80 to Week 155 during the LTE period.</description>
          </group>
          <group group_id="O3">
            <title>LTE Period: BIIB092 600 mg/4 Week</title>
            <description>Participants who received BIIB092, 600 mg, IV infusion during the PC period, continued to receive BIIB092, 600 mg, IV infusion once every 4 weeks from Week 80 to Week 155 during the LTE period.</description>
          </group>
          <group group_id="O4">
            <title>LTE Period: BIIB092 2000 mg/4 Week - Early Start</title>
            <description>Participants who received BIIB092, 2000 mg, IV infusion during the PC period, continued to receive BIIB092, 2000 mg, IV infusion once every 4 weeks from Week 80 to Week 155 during the LTE period.</description>
          </group>
          <group group_id="O5">
            <title>LTE Period: BIIB092 2000 mg/4 Week - Late Start</title>
            <description>Participants who received BIIB092-matching placebo, IV infusion during the PC period, received BIIB092, 2000 mg, IV infusion once every 4 weeks from Week 80 to Week 155 during the LTE period.</description>
          </group>
        </group_list>
        <measure>
          <title>LTE Period: Percentage of Participants With AEs and SAEs</title>
          <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose, results in death; in the view of the investigator places the participant at immediate risk of death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; is a medically important event.</description>
          <population>The safety analysis set included all randomized participants who received at least one dose of study treatment (BIIB092 or placebo).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9"/>
                    <measurement group_id="O2" value="55.1"/>
                    <measurement group_id="O3" value="58.4"/>
                    <measurement group_id="O4" value="61.3"/>
                    <measurement group_id="O5" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="10.1"/>
                    <measurement group_id="O4" value="6.0"/>
                    <measurement group_id="O5" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PC Period: Change From Baseline Over Time at Week 78 on the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score</title>
        <description>The CDR-SB is a validated clinical assessment of global function in participants with AD. The CDR is comprised of 6 domains: Memory, Orientation, Judgment and Problem Solving, Community Affairs, Home and Hobbies, and Personal Care. CDR-SB is the sum of the scores for these 6 domains. Impairment is scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or &quot;box scores&quot;, can be added together to give the CDR-SB score which ranges from 0 (none) to 18 (severe impairment).</description>
        <time_frame>Baseline, Week 78</time_frame>
        <population>FAS included all randomized participants who received study treatment (BIIB092 or placebo). As pre-specified in study protocol, 125 mg and 375 mg groups were pooled as 'Low dose' group for efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>PC Period: Placebo</title>
            <description>Participants received BIIB092-matching placebo, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
          </group>
          <group group_id="O2">
            <title>PC Period: BIIB092 Low Dose</title>
            <description>Participants received BIIB092, 125 mg, IV infusion, on Day 1 and then once every 4 weeks or BIIB092, 375 mg, IV infusion, on Day 1 and then once every 12 weeks for 76 weeks during the PC period.</description>
          </group>
          <group group_id="O3">
            <title>PC Period: BIIB092 600 mg/4 Week</title>
            <description>Participants received BIIB092, 600 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
          </group>
          <group group_id="O4">
            <title>PC Period: BIIB092 2000 mg/4 Week</title>
            <description>Participants received BIIB092, 2000 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
          </group>
        </group_list>
        <measure>
          <title>PC Period: Change From Baseline Over Time at Week 78 on the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score</title>
          <description>The CDR-SB is a validated clinical assessment of global function in participants with AD. The CDR is comprised of 6 domains: Memory, Orientation, Judgment and Problem Solving, Community Affairs, Home and Hobbies, and Personal Care. CDR-SB is the sum of the scores for these 6 domains. Impairment is scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or &quot;box scores&quot;, can be added together to give the CDR-SB score which ranges from 0 (none) to 18 (severe impairment).</description>
          <population>FAS included all randomized participants who received study treatment (BIIB092 or placebo). As pre-specified in study protocol, 125 mg and 375 mg groups were pooled as 'Low dose' group for efficacy analyses.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="116"/>
                    <count group_id="O3" value="106"/>
                    <count group_id="O4" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.07" spread="1.467"/>
                    <measurement group_id="O2" value="2.92" spread="1.620"/>
                    <measurement group_id="O3" value="3.24" spread="1.557"/>
                    <measurement group_id="O4" value="3.04" spread="1.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="2.376"/>
                    <measurement group_id="O2" value="2.10" spread="2.375"/>
                    <measurement group_id="O3" value="2.23" spread="2.987"/>
                    <measurement group_id="O4" value="1.76" spread="2.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PC Period: Percentage of Participants With Anti-BIIB092 Antibodies in Serum</title>
        <time_frame>Baseline up to Week 76</time_frame>
        <population>The ADA evaluable set is defined as participants in the FAS who have an evaluable postbaseline ADA sample.</population>
        <group_list>
          <group group_id="O1">
            <title>PC Period: Placebo</title>
            <description>Participants received BIIB092-matching placebo, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
          </group>
          <group group_id="O2">
            <title>PC Period: BIIB092 125 mg/4 Week</title>
            <description>Participants received BIIB092, 125 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
          </group>
          <group group_id="O3">
            <title>PC Period: BIIB092 375 mg/12 Week</title>
            <description>Participants received BIIB092, 375 mg, IV infusion, on Day 1 and then once every 12 weeks for 76 weeks during the PC period.</description>
          </group>
          <group group_id="O4">
            <title>PC Period: BIIB092 600 mg/4 Week</title>
            <description>Participants received BIIB092, 600 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
          </group>
          <group group_id="O5">
            <title>PC Period: BIIB092 2000 mg/4 Week</title>
            <description>Participants received BIIB092, 2000 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
          </group>
        </group_list>
        <measure>
          <title>PC Period: Percentage of Participants With Anti-BIIB092 Antibodies in Serum</title>
          <population>The ADA evaluable set is defined as participants in the FAS who have an evaluable postbaseline ADA sample.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="105"/>
                <count group_id="O5" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose through 14 weeks after last dose of study drug (Up to approximately 173 weeks)</time_frame>
      <desc>The safety analysis set included all randomized participants who received at least one dose of study treatment (BIIB092 or placebo). The all-cause mortality data and adverse events are reported for 'safety analysis set'.</desc>
      <group_list>
        <group group_id="E1">
          <title>PC Period: Placebo</title>
          <description>Participants received BIIB092-matching placebo, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
        </group>
        <group group_id="E2">
          <title>PC Period: BIIB092 125 mg/4 Week</title>
          <description>Participants received BIIB092, 125 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
        </group>
        <group group_id="E3">
          <title>PC Period: BIIB092 375 mg/12 Week</title>
          <description>Participants received BIIB092, 375 mg, IV infusion, on Day 1 and then once every 12 weeks for 76 weeks during the PC period.</description>
        </group>
        <group group_id="E4">
          <title>PC Period: BIIB092 600 mg/4 Week</title>
          <description>Participants received BIIB092, 600 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
        </group>
        <group group_id="E5">
          <title>PC Period: BIIB092 2000 mg/4 Week</title>
          <description>Participants received BIIB092, 2000 mg, IV infusion, on Day 1 and then once every 4 weeks for 76 weeks during the PC period.</description>
        </group>
        <group group_id="E6">
          <title>LTE Period: BIIB092 125 mg/4 Week</title>
          <description>Participants who received BIIB092, 125 mg, IV infusion during the PC period, continued to receive BIIB092, 125 mg, IV infusion once every 4 weeks from Week 80 to Week 155 during the LTE period.</description>
        </group>
        <group group_id="E7">
          <title>LTE Period: BIIB092 375 mg/12 Week</title>
          <description>Participants who received BIIB092, 375 mg, IV infusion during the PC period, continued to receive BIIB092, 375 mg, IV infusion once every 12 weeks from Week 80 to Week 155 during the LTE period.</description>
        </group>
        <group group_id="E8">
          <title>LTE Period: BIIB092 600 mg/4 Week</title>
          <description>Participants who received BIIB092, 600 mg, IV infusion during the PC period, continued to receive BIIB092, 600 mg, IV infusion once every 4 weeks from Week 80 to Week 155 during the LTE period.</description>
        </group>
        <group group_id="E9">
          <title>LTE Period: BIIB092 2000 mg/4 Week - Early Start</title>
          <description>Participants who received BIIB092, 2000 mg, IV infusion during the PC period, continued to receive BIIB092, 2000 mg, IV infusion once every 4 weeks from Week 80 to Week 155 during the LTE period.</description>
        </group>
        <group group_id="E10">
          <title>LTE Period: BIIB092 2000 mg/4 Week - Late Start</title>
          <description>Participants who received BIIB092-matching placebo, IV infusion during the PC period, received BIIB092, 2000 mg, IV infusion once every 4 weeks from Week 80 to Week 155 during the LTE period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Idiopathic orbital inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Large intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>COVID-19 pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Retroperitoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Breast cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Penile squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="68" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="139" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="28" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="29" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated based on lack of efficacy following the placebo-controlled period readout.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>US Biogen Clinical Trial Center</name_or_title>
      <organization>Biogen</organization>
      <phone>866-633-4636</phone>
      <email>clinicaltrials@biogen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

